Gemma Hemmings

<scp>HER2</scp> overexpression and amplification as a potential therapeutic target in colorectal cancer: analysis of 3256 patients enrolled in the <scp>QUASAR</scp>, <scp>FOCUS</scp> and <scp>PICCOLO</scp> colorectal cancer trials

Susan D. Richman, Katie Southward, Philip Chambers et al. · The Journal of Pathology · 2015 · 231 citations · Full text

Combined Epiregulin and Amphiregulin Expression Levels as a Predictive Biomarker for Panitumumab Therapy Benefit or Lack of Benefit in Patients With<i>RAS</i>Wild-Type Advanced Colorectal Cancer

Jenny F. Seligmann, Faye Elliott, Susan D. Richman et al. · JAMA Oncology · 2016 · 105 citations · Full text

Intra-tumoral heterogeneity of KRAS and BRAF mutation status in patients with advanced colorectal cancer (aCRC) and cost-effectiveness of multiple sample testing.

Susan D. Richman, Philip Chambers, Catherine Daly et al. · PubMed · 2011 · 78 citations · Full text

Genetics, Pathology, Advanced Colorectal Cancer +20

Intra-tumoral Heterogeneity of<i>KRAS</i>and<i>BRAF</i>Mutation Status in Patients with Advanced Colorectal Cancer (aCRC) and Cost-Effectiveness of Multiple Sample Testing

Susan D. Richman, Philip Chambers, Catherine Daly et al. · Analytical Cellular Pathology · 2011 · 70 citations · Full text

Cancer Pathology, Genetics, Pathology +20

Pre-trial inter-laboratory analytical validation of the FOCUS4 personalised therapy trial

Susan D. Richman, Richard Adams, Philip Quirke et al. · Journal of Clinical Pathology · 2015 · 26 citations · Full text